Related Experiment Video
Updated: May 8, 2026
05:52
Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
Sentinel lymph node biopsy for cutaneous melanoma: a 6 years study
Jaime Lima Sánchez1, M Sánchez Medina, O García Duque
1Department of Plastic, Reconstructive and Aesthetic Surgery, Universitary Hospital of Gran Canaria, Dr. Negrín, Las Palmas de Gran Canaria, Spain.
Summary
Sentinel lymph node biopsy (SLNB) is crucial for cutaneous melanoma staging. Positive SLNB results and ulcerated melanoma significantly increase recurrence and mortality risk, highlighting the importance of accurate staging.
Area of Science:
- Oncology
- Dermatology
- Surgical Pathology
Background:
- Cutaneous melanoma management relies on accurate staging.
- Sentinel lymph node biopsy (SLNB) is a key staging procedure.
- Evaluating SLNB outcomes is vital for patient prognosis.
Purpose of the Study:
- To assess the efficacy and outcomes of SLNB in cutaneous melanoma patients.
- To identify prognostic factors influencing survival and recurrence.
- To correlate SLNB status with clinicopathological features.
Main Methods:
- Retrospective analysis of 128 cutaneous melanoma patients undergoing SLNB.
- Univariate and multivariate analyses to determine predictors of mortality and SLNB status.
- Kaplan-Meier survival analysis to evaluate patient outcomes.
Main Results:
- A 27.3% SLNB positivity rate was observed.
- Higher Breslow thickness and ulceration were associated with positive SLNB and recurrence.
- SLNB-positive patients had a significantly higher recurrence rate (40%) and mortality risk.
Conclusions:
- Sentinel lymph node status is a significant independent prognostic factor in cutaneous melanoma.
- Ulcerated melanomas have a higher risk of recurrence and mortality.
- SLNB is essential for risk stratification and guiding treatment decisions.
